Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2009

Conditions
brca1 Mutation Carrierbrca2 Mutation CarrierBreast CancerHereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions
DRUG

carboplatin

DRUG

docetaxel

Trial Locations (25)

3050

Royal Melbourne Hospital, Parkville

52621

Chaim Sheba Medical Center, Tel Litwinsky

84101

Soroka University Medical Center, Beersheba

Unknown

Naharia Hospital, Nahariya

1099-023 Codex

Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, SA, Lisbon

08035

Vall d'Hebron University Hospital, Barcelona

SE-22185

Lund University Hospital, Lund

CB2 2QQ

Addenbrooke's Hospital, Cambridge

EX2 5DW

Royal Devon and Exeter Hospital, Exeter

NW3 2QG

UCL Cancer Institute, Hampstead, London

LS16 6QB

Cookridge Hospital, Leeds

LS9 7TF

Leeds Cancer Centre at St. James's University Hospital, Leeds

SE1 9RT

Guy's Hospital, London

SW3 6JJ

Royal Marsden - Surrey, London

M20 4BX

Christie Hospital, Manchester

CH63 4JY

Clatterbridge Centre for Oncology, Merseyside

NR31 6LA

James Paget Hospital, Norfolk

HA6 2RN

Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

BH15 2JB

Dorset Cancer Centre, Poole Dorset

PO3 6AD

Portsmouth Oncology Centre at Saint Mary's Hospital, Portsmouth Hants

SO16 6YD

Southampton General Hospital, Southampton

TQ2 7AA

Torbay Hospital, Torquay

EH4 2XU

Edinburgh Cancer Centre at Western General Hospital, Edinburgh

CF14 2TL

Velindre Cancer Center at Velindre Hospital, Cardiff

All Listed Sponsors
lead

University College London Hospitals

OTHER

NCT00321633 - Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer | Biotech Hunter | Biotech Hunter